Interesting article in tonights Torygraph. Quoting Dr Clive Dix, former chairman of the Vaccine Task Force.
Can you provide a link and a relevant quote please?
Essentially UK deaths flat wheras European deaths rocketing.
He credits it with UKs rapid rollout of Astra Zenica vaccine. This is a modified virus not RNA vaccine. Says it dosen't stop infection but gives you celullar immunity that enables the body to sort the virus before it does the damage. He also says the effect lasts years, possibly for life.
Yes the Oxford AZ vaccine is a good vaccine. Some people have tried to claim it's not as good as the mRNA vaccines, based mainly on antibody levels and on comparisons of rates of mild infections.
Viral vector vaccines also take longer to take effect, so in comparison trials, the efficacy of such vaccines can appear artificially lower in the first few weeks after the dose has been administered.
In contrast in the European Union smeared the Aastrazenica and used the mRNA vaccines instead. While they give a rapid jump in antibodies in lab tests they don't give cellular immunity.
By "cellular immunity", I see they mean a response through T cells, but I don't see how it can possibly be true that nRNA vaccines
don't induce a T cell response; did the author (mean to) say the T cell response
isn't as good in the mRNA vaccines?
Says the lab testing of vaccines has been flawed because it has concentrated on antibodies not T-Cell effects *over time*.
Yes indeed and we now know that T cells are key to preventing more severe symptoms.
I wonder if the focus on antibodies are due to it being easier to study them.
Thinks the mRNAs are good as a short term booster in a crisis but not a "main course" vaccine.
There is also evidence that you get better immunity by combining vaccine types, so anyone who was vaccinated with AZ should seriously consider getting an mRNA booster. A lot of people in the UK had AZ, and so the boosters are particularly useful for those people.
Does the article mention the gap between doses? Another benefit for the UK is that most people had a lengthy gap of around 10-12 weeks between doses.
The trials had to run with a short gap because we needed the efficacy data ASAP however many immunologists pointed out that a longer gap was more likely to induce a broader, more robust and longer lasting immune response, than a shorter gap. Again, if anyone didn't have such a gap, a booster dose will make up for that.
And of course there is a level of immunity no current vaccine can provide, which can only be obtained by exposure to the full virus; a vaccinated person who encounters the actual virus will develop an even greater immune response to the virus in future; once this applies to most people we will have sufficient population immunity for the whole thing to be effectively over and the virus will likely eventually be with us in the same way as the pre-existing HCoVs.